Fluvoxamine: Safety Profile in Extensive
Post-Marketing Surveillance

 

 Buy Article Permissions and Reprints

The safety profile of the selective serotonin reuptake inhibitor, fluvoxamine, has been assessed in clinical and post-marketing studies. Post-marketing surveillance provides the opportunity to assess a drug's safety in every day clinical conditions in a much greater patient population than in clinical trials and therefore serves as a useful tool to detect signals for adverse effects with an incidence of less than 1 : 10,000. The safety profile of fluvoxamine was evaluated based on data from 17 years of global post-marketing surveillance in an estimated 28 million patients exposed to fluvoxamine. A total of 6,658 adverse drug reaction reports received from world-wide sources were reviewed and analysed. Post-marketing surveillance data confirmed the favourable safety profile already observed in clinical and post-marketing studies. A remarkably low level of suicidality, switch to mania, and sexual dysfunction was found. Serotonin syndrome appeared to be a very rare complication of fluvoxamine treatment. No signals for drug interactions unknown so far were identified. Withdrawal symptoms were observed in everyday clinical conditions, which were generally mild and resolved spontaneously. However, no cases suggestive for drug dependence have been reported. In conclusion, the data presented underlined that fluvoxamine offers a safe and well-tolerated option in the treatment of depression and obsessive-compulsive disorder.

References

• 1 Angst J. Sexual problems in healthy and depressed persons.  Int Clin Psychopharmacol. 1998;  13 (6) S1-S4
  CrossrefPubMedGoogle Scholar
• 2 Banki C M. Prophylactic potential of selective reuptake inhibitors in suicidal patients.  Int Clin Psychopharmacol. 1995;  9 (4) 61-65
  PubMedGoogle Scholar
• 3 Barefoot J C, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample.  Circulation. 1996;  93 1976-1980
  CrossrefPubMedGoogle Scholar
• 4 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.  Clin Pharmacokinet. 1996;  31 444-469
  CrossrefPubMedGoogle Scholar
• 5 Benazzi F. SSRI discontinuation syndrome related to fluvoxamine (letter).  J Psychiat Neurosci. 1998;  23 94
  PubMedGoogle Scholar
• 6 Berlin C S. Fluoxetine withdrawal symptoms (letter).  J Clin Psychiatry. 1996;  57 93-94
  PubMedGoogle Scholar
• 7 Bertschy G, Eap C B, Powell K, Baumann P. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.  Ther Drug Mon. 1996;  18 570-572
  PubMedGoogle Scholar
• 8 Bryois C, Ferrero F. Mania induced by citalopram (letter).  Arch Gen Psychiatry. 1994;  51 664-665
  PubMedGoogle Scholar
• 9 Burrai C, Bocchetta A, del Zompo M. Mania and fluvoxamine (letter).  Am J Psychiatry. 1991;  148 1263-1264
  PubMedGoogle Scholar
• 10 Carrillo J A, Ramos S I, Herraiz A G, Llerena A, Agundez J A, Berecz R, Duran M, Benitez J. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.  J Clin Psychopharmacol. 1999;  19 494-499
  CrossrefPubMedGoogle Scholar
• 11 Christensen R C. Paroxetine-induced psychotic mania (letter).  Am J Psychiatry. 1995;  152 1399-1400
  PubMedGoogle Scholar
• 12 Code of Federal Regulations .Title 21, Chapter 1. Food and Drug Administration, Department of Health and Human Services. Part 312.32. IND Safety Reports 1999: revised 1 April
• 13 Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, Maryland USA; FDA Center for Drug Evaluation and Research 1989
• 14 Bankowski Z, Bruppacher R, Crusius I, Gallagher J, Kremer G, Venulet J (eds) Reporting adverse drug reactions. Definitions of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS) 1999
  Google Scholar
• 15 CPMP Position Paper on SSRIs and Dependency/Withdrawal Reactions. EMEA/CPMP/2775/99
• 16 Daniel W A. The influence of SSRIs on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.  Exp Toxic Pathol. 1991;  51 309-314
  PubMedGoogle Scholar
• 17 DeVane C L. Differential pharmacology of newer antidepressants.  J Clin Psychiatry. 1998;  59 (20) 85-93
  PubMedGoogle Scholar
• 18 Downs J, Ward J, Farmer R. Preoccupation with suicide in patients treated with fluoxetine (letter, comment).  Am J Psychiatry. 1991;  148 1090-1091
  PubMedGoogle Scholar
• 19 Eap C B, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.  J Clin Psychopharmacol. 2000;  17 113-117
  PubMedGoogle Scholar
• 20 Ebert D, Albert R, May A, Merz A, Murata H, Stosiek I, Zahner B. The serotonin syndrome and psychosis-like side effects of fluvoxamine in clinical use - an estimation of incidence.  Eur Neuropsychopharmacol. 1997;  7 71-74
  CrossrefPubMedGoogle Scholar
• 21 Edwards J G, Inman W HW, Wilton L, Pearce G L. Prescription-event monitoring of 10401 patients treated with fluvoxamine.  Br J Psychiatry. 1994;  164 387-395
  PubMedGoogle Scholar
• 22 EMEA Human Medicines Evaluation Unit. Notice to Marketing Authorisation Holders .Pharmacovigilance Guidelines (CPMP/PhVWP/108/99 corr.). London; 1999: 29 January
• 23 Fava G A, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation (letter).  J Clin Psychopharmacol. 1995;  15 374-375
  CrossrefPubMedGoogle Scholar
• 24 Feder R. Fluoxetine-induced mania (letter).  J Clin Psychiatry. 1990;  51 524-525
  PubMedGoogle Scholar
• 25 Fernando A T, Schwader P. A case of citalopram withdrawal (letter).  J Clin Psychopharmacol. 2000;  20 581-582
  CrossrefPubMedGoogle Scholar
• 26 Fleishaker J C, Hulst L K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluovoxamine.  Eur J Clin Pharmacol. 1994;  46 35-39
  PubMedGoogle Scholar
• 27 Frank A, Anderson C, Rubinstein D. Frequency of sexual dysfunction in “normal” couples.  N Engl J Med. 1978;  299 111-115
  CrossrefPubMedGoogle Scholar
• 28 Ghaziuddin M. Mania induced by sertraline in a prepubertal child (letter).  Am J Psychiatry. 1994;  151 944
  PubMedGoogle Scholar
• 29 Gillman P K. Serotonin syndrome: history and risk.  Fundam Clin Pharmacol. 1998;  12 482-491
  PubMedGoogle Scholar
• 30 Goodman W K, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.  J Clin Psychiatry. 1997;  58 (5) 32-49
  PubMedGoogle Scholar
• 31 Hartmann K, Koller-Doser A, Kuhn M. Postmarketing Safety Information: How useful are spontaneous reports?.  Pharmacoepidemiol Drug Safety. 1999;  8 65-71
  CrossrefPubMedGoogle Scholar
• 32 Hegerl U, Bottlender R, Gallinat J, Kuss H J, Ackenheil M, Möller H J. The serotonin syndrome scale: first results on validity.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 96-103
  CrossrefPubMedGoogle Scholar
• 33 Hemeryck A, De Vriendt C, Belpaire F M. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.  Eur J Pharmacol. 1999;  54 947-951
  PubMedGoogle Scholar
• 34 Hewer W, Rost W, Gattaz W F. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.  Eur Arch Psychiatry Clin Neurosci. 1995;  246 1-6
  PubMedGoogle Scholar
• 35 Hochberg H M, Kanter D, Houser V P. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.  Pharmacopsychiatry. 1995;  28 253-256
  PubMedGoogle Scholar
• 36 Howland R H. Induction of mania with serotonin reuptake inhibitors.  J Clin Psychopharmacol. 1996;  16 425-427
  CrossrefPubMedGoogle Scholar
• 37 ICH Harmonised Tripartite Guideline .Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs. Recommended for adoption at Step 4 of the ICH process on November 6th, 1996. 
• 38 ICH Harmonised Tripartite Guideline .Definitions and Standards for Expedited Reporting. Recommended for adoption at Step 4 of the ICH process on October 27th, 1994. 
• 39 Jeppesen U, Gram L F, Vistisen K, Loft S, Poulsen H E, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine and paroxetine.  Eur J Clin Pharmacol. 1996;  51 73-78
  CrossrefPubMedGoogle Scholar
• 40 Jeppesen U, Rasmussen B B, Brosen K. Fluvoxamine inhibitis the CYP2C19-catalysed bioactivation of chloroguanide.  Clin Pharmacol Ther. 1997;  62 (3) 279-286
  CrossrefPubMedGoogle Scholar
• 41 Kasper S, Schindler S, Neumeister A. Risk of suicide in depression and its implication for psychopharmacological treatment.  Int Clin Psychopharmacol. 1996;  11 71-79
  PubMedGoogle Scholar
• 42 Laird L K, Lydiard R B, Morton W A, Steele T E, Kellner C, Thompson N M, Ballender J C. Cardiovascular effects of imipramine, fluvoxamine and placebo in depressed outpatients.  J Clin Psychiatry. 1993;  54 224-228
  PubMedGoogle Scholar
• 43 Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine.  Acta Psychiatr Scand. 1993;  88 369-371
  PubMedGoogle Scholar
• 44 Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review.  J Psychosom Res. 2000;  48 379-391
  CrossrefPubMedGoogle Scholar
• 45 Letizia C, Kapik B, Flanders W D. Suicidal risk during controlled clinical investigations of fluvoxamine.  J Clin Psychiatry. 1996;  57 415-421
  PubMedGoogle Scholar
• 46 LoCurto M J. The serotonin syndrome.  Emerg Med Clin N Am. 1997;  15 665-675
  PubMedGoogle Scholar
• 47 Louie A K, Lannon R A, Ajari L J. Withdrawal reaction after sertraline discontinuation (letter).  Am J Psychiatry. 1994;  151 450-451
  PubMedGoogle Scholar
• 48 Lu M L, Lane H Y, Chen K P, Su M H, Chang W H. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.  J Clin Psychiatry. 2000;  61 594-599
  CrossrefPubMedGoogle Scholar
• 49 Martin R M, Mann R D, Hands D E, Tomlin M, Emerson A. Design of a pilot prospective cohort study of adverse events monitored by hospital pharmacists.  Int J Pharmaceut Med. 1999;  13 11-16
  PubMedGoogle Scholar
• 50 Martin T G. Serotonin syndrome.  Ann Emerg Med. 1996;  28 520-526
  CrossrefPubMedGoogle Scholar
• 51 Medicines Control Agency, Committee on Safety of Medicines .In focus: Selective Serotonin Reuptake Inhibitors. Current problems in Pharmacovigilance. September 2000 26: 11-12
• 52 Mesdjian E, Seree E, Charvet B, Mirrione A, Bourgarel R V, Desobry A, Barra Y. Metabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies.  Life Sci. 1999;  64 827-835
  CrossrefPubMedGoogle Scholar
• 53 Montejo-Gonzales A L, Llorca G, Izquierdo J A, Ledesma A, Bousono M. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.  J Sex Marital Therapy. 1997;  23 (3) 176-194
  CrossrefPubMedGoogle Scholar
• 54 Montgomery S A. Suicide and antidepressants.  Drugs. 1992;  43 (2) 24-31
  PubMedGoogle Scholar
• 55 Musselman D L, Evans D L, Nemeroff C B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment.  Arch Gen Psychiatry. 1998;  55 580-592
  PubMedGoogle Scholar
• 56 Nafziger A N. et al . Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.  J Clin Psychiatry. 1999;  60 (3) 187-190
  PubMedGoogle Scholar
• 57 Nathan S G. The epidemiology of DSM-III psychosexual dysfunctions.  J Sex Mar Therap. 1986;  12 267-282
  PubMedGoogle Scholar
• 58 Nemeroff C B, Musselman D L, Evans D L. Depression and cardiac disease.  Depr Anxiety. 1998;  8 (1) 71-79
  PubMedGoogle Scholar
• 59 Oldroyd J. Paroxetine-induced mania (letter).  J Am Acad Child Adolesc Psychiatry. 1997;  36 721-722
  PubMedGoogle Scholar
• 60 Ottevanger E A. Fluvoxamine activity profile with special emphasis on the effect on suicidal ideation.  Eur J Clin Res. 1991;  1 47-54
  PubMedGoogle Scholar
• 61 Pacheco L, Malo P, Aragues E, Etxebeste M. More cases of paroxetine withdrawal syndrome (letter).  Br J Psychiatry. 1996;  169 384
  PubMedGoogle Scholar
• 62 Pan L P, Wijnant P, De Vriendt C, Rosseel M T, Belpaire F M. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.  Br J Clin Pharmacol. 1997;  44 557-564
  CrossrefPubMedGoogle Scholar
• 63 Pataki C S. Mood disorders and suicide in children and adolescents. In: Saddock BJ, Saddock VA (eds) Comprehensive Textbook of Psychiatry. 7th Edition. Lippincott; Williams & Wilkins 2000: 2740-2757
  Google Scholar
• 64 Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants.  Brit J Psychiatry. 1994;  165 835-836
  PubMedGoogle Scholar
• 65 Prager G, Stollmaier W, Prager R. Sicherheit und Verträglichkeit von Fluvoxamin bei kardialen Risikopatienten (Safety and tolerability of fluvoxamine in cardiovascular risk patients, German).  Tw Neurology Psychiatric. 1991;  5 548-562
  PubMedGoogle Scholar
• 66 Preskorn S H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.  Clin Pharmacokinet. 1997;  32 (1) 1-21
  PubMedGoogle Scholar
• 67 Price J S, Waller P C, Wood S M, MacKay A V. A comparison of the postmarketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal.  Brit J Clin Pharmacol. 1996;  42 757-763
  PubMedGoogle Scholar
• 68 Rechlin T. The effect of amitriptyline, doxepin, fluvoxamine and paroxetine treatment on heart rate variability.  J Clin Psychopharmacol. 1994;  14 392-395
  PubMedGoogle Scholar
• 69 Rothschild A J. Sexual side effects of antidepressants.  J Clin Psychiatry. 2000;  61 (11) 28-36
  PubMedGoogle Scholar
• 70 Schatzberg A, Haddad P, Kaplan E M, Lejoyeux M, Rosenbaum J F, Young A H, Zajecka J. Serotonin re-uptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel.  J Clin Psychiatry. 1997;  58 5-10
  PubMedGoogle Scholar
• 71 Schmider J, Greenblatt D J, von Moltke L L, Karsov D, Shader R I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin parahydroxylation.  Br J Clin Pharmacol. 1997;  44 495-498
  CrossrefPubMedGoogle Scholar
• 72 Schmidtke A, Bille-Brahe U, DeLeo D, Kerkhof A, Bjerke T, Crepet P. et al . Attempted suicide in Europe: rates, trends and sociodemographic characteristics of suicide attempters during the period 1989 - 1992. Results of the WHO/EURO multicentre study on parasuicide.  Acta Psychiatr Scand. 1996;  93 327-338
  PubMedGoogle Scholar
• 73 Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.  Psychiatry Clin Neurosci. 1999;  53 593-597
  PubMedGoogle Scholar
• 74 Sporer K A. The serotonin syndrome.  Drug Safety. 1995;  13 94-104
  PubMedGoogle Scholar
• 75 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713
  PubMedGoogle Scholar
• 76 Stoll A L, Mayer P V, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen B M, Tohen M. Antidepressant-associated mania: a controlled comparison with spontaneous mania.  Am J Psychiatry. 1994;  151 1642-1645
  PubMedGoogle Scholar
• 77 Strik J JMH, Honig A, Lousberg R, Cheriex E C, Van Praag H M. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.  Int Clin Psychopharmacol. 1998;  13 263-267
  PubMedGoogle Scholar
• 78 Szabadi E. Fluvoxamine withdrawal syndrome.  Br J Psychiat. 1992;  160 283-284
  PubMedGoogle Scholar
• 79 Teicher M H, Glod C, Cole J O. Emergence of intense suicidal preoccupation durin fluoxetine treatment.  Am J Psychiat. 1990;  147 207-210
  CrossrefPubMedGoogle Scholar
• 80 Van Harten J. Overview of the pharmacokinetics of fluvoxamine.  Clin Pharmacokinet. 1995;  29 (1) 1-9
  PubMedGoogle Scholar
• 81 Venkataraman S, Naylor M W, King C A. Mania associated with fluoxetine treatment in adolescents.  J Am Acad Child Adolesc Psychiatry. 1992;  31 276-281
  PubMedGoogle Scholar
• 82 Wagner W, Vause E W. Fluvoxamine. A review of global drug-drug interaction data.  Clin Pharmacokinet. 1995;  29 (1) 26-32
  PubMedGoogle Scholar
• 83 Wagner W, Zaborny B A, Gray T E. Fluvoxamine. A review of its safety profile in world-wide studies.  Int Clin Psychopharmacol. 1994;  9 223-227
  PubMedGoogle Scholar
• 84 Waldinger M D, Hengeveld M W, Zwinderman A H. et al . Effect of SSRI antidepressants on ejaculation: a double-blind, randomised, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline.  J Clin Psychopharmacol. 1998;  18 274-281
  CrossrefPubMedGoogle Scholar
• 85 Ware M R. Fluvoxamine: a review of the controlled trials in depression.  J Clin Psychiatry. 1997;  58 (5) 15-23
  PubMedGoogle Scholar
• 86 Wilde M, Plosker G L, Benfield P. Fluvoxamine. An updated review of its pharmacology and therapeutic use in depressive illness.  Drugs. 1993;  46 895-924
  PubMedGoogle Scholar
• 87 Wilson W H, Higano H, Papadatos Y, Kelwala S, Ban T A. A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers.  Brit J Clin Pharmacol. 1983;  15 385S-392S
  PubMedGoogle Scholar

Dr. Robert Buchberger

Solvay Pharmaceuticals GmbH

Hans-Böckler-Allee 20

30173 Hannover

Germany